DCIS of the Breast: A Look towards Discovery and Advancements in the Field by Henry Mark Kuerer et al.
DCIS of the Breast: A Look towards Discovery
and Advancements in the Field
Henry Mark Kuerer, MD, PhD, FACS,1,2,3 Lisa S. Wiechmann, MD,1,2 and
Lajos Pusztai, MD, PhD1,2
1Departments of Surgical Oncology (HMK), Breast Medical Oncology (LP), The University of Texas M. D. Anderson Cancer
Center, Houston, TX, USA
2Baylor Breast Center (LSW), Baylor College of Medicine, Houston, TX, USA
3Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd.,
Houston, TX 77030, USA
Somany assumptions and questions remain regarding
ductal carcinoma in situ (DCIS). We overtreat the
majority of patients with DCIS as this entity is gener-
ally not immediately life threatening. For many
patients with an initial diagnosis of DCIS, progression
to invasive cancer (if at all) may be over a period of
several decades. What are our treatments for DCIS?
We perform surgery, utilize radiation in most, use
Tamoxifen in many cases,1 and we are even beginning
trials to test other novel systemic biologic agents for the
disease.2,3 However, the use of the word ‘‘treatment’’ is
probably our ﬁrst and most obvious mistake when we
talk aboutDCIS.We really need to begin to talk about
prevention when we mention DCIS. We treat DCIS to
prevent invasive breast cancer; just as we may treat
patients with very strong family histories or known
genetic predisposition to cancer, or LCIS, or atypical
hyperplasia. Our fundamental understanding of the
biology and clinical behavior of DCIS is not clear.
Some essential questions regarding DCIS need to
be examined systematically:
1. Can we identify patients with DCIS who are the
most likely to develop invasive cancer?
2. With no additional therapy, what is the true
incidence of development of invasive cancer
following the diagnosis of DCIS based on the
age of our patients at diagnosis and other yet to be
deﬁned biologic parameters?
3. Can we eliminate all ‘‘treatments’’ for DCIS and
follow certain patient subsets with exceptionally
good prognosis based on known and yet to be
deﬁned biologic parameters?
4. Can we identify a true molecular signature that
will accurately differentiate cases of DCIS that can
never harm our patients from potentially aggres-
sive DCIS?
5. Can we safely tailor treatment modalities includ-
ing surgery, radiation therapy, and endocrine
treatment for individual patients using clinical
and biological information of the disease?
6. What imaging modalities can be developed that
will help us best visualize those at risk for
concurrent invasive cancer or demonstrate transi-
tion from DCIS to invasive disease conclusively on
subsequent follow up?
7. What are the immunologic mechanisms present in
healthy patients with DCIS that are likely to be at
work in the prevention of the development inva-
sive breast cancer?
8. What strategies are needed at a national and
global level to facilitate answering these questions
and move the ﬁeld forward?
In ‘‘Correlation of Levels and Patterns of Genomic
Instability with Histologic Grading of DCIS,’’ Ells-
worth et al.4 ampliﬁed a panel of 52 microsatellite
markers, genotyped, and analyzed them to poten-
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tially develop DCIS genomic patterns that correlate
with clinical and pathologic classiﬁcation of DCIS.
The investigators found patterns of allelic instability
to add further support to previous reported hypo-
thetical models in which DCIS develops along two
discreet pathways. Speciﬁcally, Ellsworth et al.4 have
shown that physical loss of chromosome 16q appears
essential for the development of well-differentiated
DCIS, while allelic instability at 6q, 25q27, 8q24,
9p21, 13q14, and 17p13.1 are associated with the
development of poorly differentiated lesions.
This study advances our understanding of the ge-
netic changes that are associated with the histological
appearance of disease but fails to answer the question
of which genetic changes can predict those patients at
risk for development of invasive breast cancer.
However, the value of these ﬁndings should not be
underestimated as they are likely a bridge to further
advancements in the ﬁeld. The precise relationship
between DCIS and invasive breast cancer remains to
be elucidated. The advent and widespread use of
screening mammography has led to increasing
detection of DCIS in the USA and detection rates of
this entity are expected to increase exponentially as
the our more healthy global population of women
increase their life expectancy and as more developing
countries begin screening programs. The hunt for
molecular markers or signatures that will accurately
predict the nature of the DCIS progression to inva-
sive breast cancer has been extremely challenging and
limited primarily by the lack of large repositories of
tissue samples and extensive clinical follow-up. A
critical need exists for a concerted national program
of patients with DCIS, clinicians, and basic scientists
to identify molecular parameters of DCIS associated
with an actual risk to the life of our patients. The time
to advance the ﬁeld and our understanding of DCIS
is now.
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